Matched Conjugation Platforms Unlock the Therapeutic Potential of Heterobifunctional Degrader-Antibody Conjugates Through mAb-like Pharmacokinetics at High DAR and Excellent In Vivo Efficacy

• Payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
• Here we present novel conjugation technologies for stable conjugation and traceless release of heterobifunctional degraders
• Resulting DACs are homogenous with high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy

Speakers:

Marc-Andre Kasper

Vice President, Chemistry & Early Discovery

Tubulis GmbH